Insulet Corp (PODD) Stock Analysis
Verdict: HOLD
Omnipod 5's category leadership and cash generation face emerging patch-pump competition and analyst margin compression fears.
Investment score: 61/100
Analysis as of
Is Insulet Corp stock worth reviewing? AI model thesis
The model views Insulet as an established medtech leader experiencing cyclical valuation compression. While short-term technicals remain weak following competitive FDA developments, strong core fundamentals (71.08% gross margin, $377.7M FCF) support valuation floor stability.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Insulet Corp opportunities and risks
What speaks for PODD
- Pharmacy Channel Advantage and Recurring Disposable Revenue
What speaks against PODD
- Emerging Direct Competition in Tubeless Patch Pumps
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PODD | 26.2x | 3.2x | 15.9x | 71.1% | 12.3% | 3.1% |
| ZBH | 23.4x | 2.2x | 13.2x | 69.9% | 9.5% | 9.8% |
| PEN | 77.8x | 8.3x | 56.5x | 67.8% | 10.7% | 1.7% |
| BAX | n/a | 1.1x | 26.2x | 30.1% | -9.3% | 5.6% |
| GMED | 19.0x | 3.2x | 11.1x | 68.5% | 17.0% | 7.4% |
| GKOS | n/a | 15.7x | n/a | 79.1% | -30.7% | -0.1% |
| Peer median | 19.0x | 3.2x | 13.2x | 68.5% | 9.5% | 5.6% |
Frequently asked questions about Insulet Corp (PODD)
Is PODD stock a good investment?
The cached TradeMates AI model rates Insulet Corp as HOLD with an investment score of 61/100. The model views Insulet as an established medtech leader experiencing cyclical valuation compression. While short-term technicals remain weak following competitive FDA developments, strong core fundamentals (71.08% gross margin, $377.7M FCF) support valuation floor stability. This is algorithmic model output, not personal investment advice.
Is PODD stock a buy?
The TradeMates model verdict for PODD is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.